HIV-Infected Individuals Who Delay, Decline, or Discontinue Antiretroviral Therapy: Comparing Clinic- and Peer-Recruited Cohorts by Marya Gwadz et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PUBLIC HEALTH
ORIGINAL RESEARCH ARTICLE
published: 16 July 2014
doi: 10.3389/fpubh.2014.00081
HIV-infected individuals who delay, decline, or discontinue
antiretroviral therapy: comparing clinic- and peer-recruited
cohorts
Marya Gwadz 1*, Elizabeth Applegate1, Charles Cleland 1, Noelle Regina Leonard 1, Hannah Wolfe2,
Nadim Salomon3, Mindy Belkin1, Marion Riedel 4, Angela Banfield 1, Lisa Sanfilippo1, Andrea Wagner 1,
Donna Mildvan5 and The Heart to Heart Collaborative ResearchTeam
1 Center for Drug Use and HIV Research (CDUHR), NewYork University, College of Nursing, NewYork, NY, USA
2 Spencer Cox Center for Health, Mount Sinai St. Luke’s-Roosevelt Hospital Center, NewYork, NY, USA
3 Peter Kruger Clinic, Mount Sinai Beth Israel Medical Center, NewYork, NY, USA
4 School of Social Work, Columbia University, NewYork, NY, USA
5 Department of Infectious Diseases, Mount Sinai Beth Israel Medical Center, NewYork, NY, USA
Edited by:
Maria Prins, Public Health Service of
Amsterdam, Netherlands
Reviewed by:
Anthony Jaworowski, Burnet
Institute, Australia
Arjan E. R. Bos, Open University of
the Netherlands, Netherlands
*Correspondence:
Marya Gwadz, NewYork University
College of Nursing, 726 Broadway,
10th Floor, NewYork, NY 10003, USA
e-mail: mg2890@nyu.edu
A substantial proportion of persons living with HIV/AIDS (PLHA) delay, decline, or dis-
continue antiretroviral therapy (ART) when it is medically indicated (40–45%), largely
African-Americans and Latinos/Hispanics. This study explores the feasibility of locating
PLHA, who are not on ART (PLHA-NOA) through clinics and peer-referral; compares the
two cohorts on multi-level barriers to ART; and examines readiness to initiate/reinitiate
ART, a predictor of treatment outcomes. We recruited adult HIV-infected African-American
and Latino/Hispanic PLHA-NOA through HIV hospital clinics and peer-referral in 2012–2013.
Participants were engaged in structured 1-h assessments with reliable/valid measures on
barriers to ART. We found that recruitment through peers (63.2%, 60/95) was more fea-
sible than in clinics (36.8%, 35/90). Participants were 48.0 years old and had lived with
HIV for 14.7 years on average, and 56.8% had taken ART previously. Most (61.1%) were
male and African-American (76.8%), and 23.2% were Latino/Hispanic. Peer-recruited par-
ticipants were older, had lived with HIV longer, were less engaged in HIV care, and were
more likely to have taken ART previously. The cohorts differed in reasons for discontinuing
ART. Levels of ART knowledge were comparable between cohorts (68.5% correct), and
there were no differences in attitudes toward ART (e.g., mistrust), which were in the neu-
tral range. In bivariate linear regression, readiness for ART was negatively associated with
physician mistrust (B=−10.4) and positively associated with self-efficacy (B=5.5), pos-
itive outcome expectancies (B=6.3), beliefs about personal necessity of ART (B=17.5),
and positive internal norms (B=7.9). This study demonstrates the feasibility of engaging
this vulnerable population through peer-referral. Peer-recruited PLHA evidence particularly
high rates of risk factors compared to those in hospital clinics. Interventions to support
ART initiation and continuation are sorely needed for both subgroups.
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INTRODUCTION
The proportion of persons living with HIV/AIDS (PLHA) who ini-
tiate antiretroviral therapy (ART) in a timely fashion has increased
in recent decades (1, 2). Yet a substantial proportion of PLHA is
not taking ART when it is medically indicated, because they decline
or delay ART when it is offered, discontinue ART, or do not oth-
erwise have good access to ART regimens (3, 4). We refer to this
population of PLHA not on ART when it is medically indicated
as “PLHA-NOA.” The individual, community, and societal-level
consequences of PLHA not gaining access to ART are grave, and
include high rates of morbidity, reduced quality of life, earlier mor-
tality, viral resistance (when ART is discontinued), increased risk
of transmission of HIV to others, and high health care costs (5–9).
Studies characterizing rates of diagnosis with HIV, linkage to
and retention in care, ART uptake, and viral suppression, called
the “HIV continuum of care” or “treatment cascade,” highlight the
very serious problem of PLHA-NOA. A 2012 Centers for Disease
Control and Prevention (CDC) report described a number of gaps:
of the 1.1 million Americans living with HIV, 63% are not retained
in care; 67% have not been prescribed ART, and only one-quarter
have suppressed viral load (3). Based on these CDC data, we con-
servatively estimate that 40–50% of PLHA in the US have unmet
need for ART, mainly those who are also not well engaged in care.
These high estimates of PLHA-NOA are supported by data on ART
discontinuation, where up to 40–50% of those who initiate ART
discontinue their regimens at least once within a year (10–12).
The majority of PLHA in the US are from African-American
and Latino/Hispanic backgrounds (approximately 60%), and like-
wise, the majority of PLHA-NOA is from racial/ethnic minority
backgrounds (3, 13). Indeed, the racial and ethnic background of
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PLHA-NOA is relevant because barriers to ART tend to vary across
racial/ethnic groups, and interventions to reduce barriers to health
can be culturally targeted to the factors with the greatest relevance
to various subgroups of PLHA (14, 15).
In contrast to the large literature on ART adherence, little is
known about the factors that drive the problem of PLHA-NOA.
In the next section, we consider factors believed to contribute to
discontinuation, delay, and decline of ART, and poor access to
ART. In light of the complexity of the problem of PLHA-NOA,
the present study was guided by the theory of triadic influence,
a multi-level social-cognitive theory that examines three “streams
of influence”on health behavior: individual/attitudinal, social, and
structural (16).
At the individual/attitudinal level of influence, poor under-
standing of HIV treatment as well as misconceptions about ART
appears to contribute to PLHA-NOA(17). PLHA may not perceive
the need for ART, particularly when they feel healthy (18). African-
American and Latino/Hispanic PLHA evidence a number of HIV-
and health care-related attitudes and beliefs rooted in culture and
U.S. history. Specifically, these beliefs are partly grounded in the
history of past abuses of people from racial/ethnic minority back-
grounds by medical research, the medical establishment, and larger
society, which have been described as resonating with present-day
exclusion, discrimination, and structural racism (13, 19–21). The
Tuskegee Syphilis study is perhaps the most emblematic example
of past abuses, and this and other examples of maltreatment con-
tribute to fear and distrust, not only of ART, but also the HIV care
system, health care providers, and other larger societal structures
(22, 23). Further, negative perceptions of ART, particularly fear of
side effects, are common and can impede acceptance of ART (24–
26), as do negative outcome expectancies, that is, the belief ART is
ineffective and/or toxic (26). Moreover, low self-efficacy for man-
aging and adhering to ART may reduce ART initiation (24, 25, 27).
These attitudes and intentions appear to interact to contribute to
a belief that ART is unnecessary or even harmful that it cannot be
tolerated or successfully managed, and/or create fears that one is
not “ready” to manage an ART regimen (24, 28). Indeed, a num-
ber of studies have argued that readiness for ART is an important
latent construct that influences both adherence and treatment out-
comes, which can therefore be targeted in behavioral interventions
to improve ART outcomes (29, 30). Yet fears and negative health
beliefs do not preclude interest in ART or even ART initiation.
PLHA, including those from racial/ethnic minority backgrounds,
can simultaneously evidence curiosity about and willingness to
initiate treatment options, along with fear and negative health
beliefs (31, 32).
Persons living with HIV/AIDS’ health status can impede uptake
of ART. PLHA face challenges accessing HIV health care (3, 33)
and sub-optimal engagement in care is common (3, 5). Those
attending fewer health care visits are less likely to initiate ART
(34), suggesting that those with poor access to care are less likely
to use ART, those who do not wish to initiate ART elect to attend
fewer health care appointments in order to avoid such discussions
with providers, and that barriers to ART also impede access to
care (35). Moreover “competing priorities” interfere with initia-
tion of ART, primary among them are alcohol and non-injection
drug use problems (36, 37), injection drug use in some studies,
mental health symptoms, and unstable housing (17, 27, 38–40).
Yet competing priorities, while serious, do not necessarily pre-
clude individuals from initiating and sustaining ART with high
adherence. Past studies have shown these types of barriers can
be ameliorated through interventions, and that among popula-
tions with competing priorities, rates of ART initiation with high
adherence improve with clinical care, behavioral interventions,
and support (36).
Social-level barriers include fear of HIV-related stigma that
might arise if others were aware of their HIV diagnosis. More-
over, PLHA who perceive negative peer norms regarding ART, that
is, that their peers tend to avoid ART or view ART negatively, or
would view the PLHA negatively if he/she took ART, may be less
likely to initiate and sustain these regimens (41, 42). PLHA’s rela-
tionships with health care providers play a critical role in ART
initiation. National HIV treatment guidelines recommend that
providers evaluate and manage factors that might impede adher-
ence to ART (43). Yet some studies suggest that providers may
delay recommending ART to patients because of concerns that
patients will be unable to benefit from or adhere to ART (4, 25,
26, 44). Wong and colleagues (4) found that African-Americans
initiate ART later than Whites regardless of providers’ attitude
toward prescribing ART, but that provider beliefs led to delayed
prescribing of ART to Latinos/Hispanics, women, and those with
low socioeconomic status (4). The problem of PLHA-NOA is
complicated by the fact that some patients are hesitant to tell
their providers that they are not taking ART, for example in cases
when providers have prescribed ART and assume patients have
initiated it (45).
Structural barriers are features of the external environment
(economic, geographic, policy, organizational or other) that limit
individuals’ options (46). Aspects of the HIV care setting including
its location, structure, policies, and quality of care can promote or
impede access to ART (47, 48). While few studies have compared
the initiation of ART, adherence, or retention in care between
patients in comprehensive hospital HIV clinics vs. those in com-
munity care settings, recent work suggests that rates of initiation
of ART are similar between the two settings, although community-
based clinics may see patients earlier in their HIV disease as a result
of outreach efforts (49, 50). Yet another recent study suggests that
patients in community-based clinics have better health care reten-
tion but those in hospital-based clinics are more likely to be virally
suppressed (51). Thus the setting where PLHA receive care may
influence patterns of ART initiation. A second structural barrier
to ART may be the short health care encounter, which is not well
designed to overcome multiple, intersecting barriers to ART (40).
Last, in some locations, vulnerable PLHA are offered the chance to
sell medications back to a pharmacy, an illegal activity that thereby
decreases uptake of ART (51).
The HIV continuum of care models indicate that PLHA-NOA
can be found in clinic settings (3). Yet little is known about strate-
gies to seek out PLHA-NOA who do not regularly attend clinic vis-
its. Because PLHA tend to be socially linked (52), peer-recruitment
methods may hold promise for seeking out and engaging PLHA-
NOA, including those with less frequent involvement in care (52,
53). Thus one aim of the present study was to explore the feasibility
of both clinic- and peer-based strategies for locating and engaging
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PLHA-NOA into a research study on barriers to ART initiation
and continuation.
This is an exploratory study of an under-studied population,
PLHA-NOA, focused on the population of African-American and
Latino/Hispanic individuals PLHA who comprise the majority of
this vulnerable group. The aims of the study were to extend past
research on PLHA-NOA that has focused mainly on clinic settings
and (1) explore the feasibility of recruiting PLHA-NOA from HIV
hospital clinics compared to peer-referral, and gain insights to
refine recruitment procedures for future research; (2) describe
the clinic and peer-recruited cohorts and compare them with
respect to socio-demographic, background, and health character-
istics, including reasons for delaying/declining or discontinuing
ART, as appropriate; (3) compare individual/attitudinal-, social-
, structural-level factors hypothesized to impede ART initiation
between the two groups; (4) identify factors that predict “readi-
ness” to initiate ART, including whether cohort (clinic vs. peer-
recruited) and past use of ART are associated with readiness to
initiate ART; and (5) explore whether those who have taken ART
in the past differ from those who have never taken ART on back-
ground, health, and other factors. We hypothesized that it would
be more feasible to locate and engage PLHA-NOA in clinic set-
tings than through peers, because they have a prior connection
to the setting, which could facilitate linkage to the study. Because
little is known about the barriers to ART for PLHA-NOA, we do
not present hypotheses regarding how clinic and peer-recruited
cohorts may differ with respect to these factors.
MATERIALS AND METHODS
Participants were 95 individuals recruited in HIV hospital clinics
(N = 35) and through peer-referral (N = 60), who were medically
eligible for ART but not taking ART, as part of an intervention
development study on increasing ART initiation in this group.
The clinic-recruitment study component was located in two large
hospital-based HIV clinics in New York City, each serving between
1000 and –4000 PLHA, primarily those from African-American
and Latino/Hispanic backgrounds, where prior to the study an
estimated 10% of the patient population had delayed, declined, or
stopped ART when it was medically indicated. The peer-referral
component, described below, was located at a project field site.
Recruitment procedures for the two cohorts differed in a mod-
est number of respects, as we describe below, although eligibility
criteria were the same. Procedures were approved by the Institu-
tional Review Boards at the two collaborating hospitals and New
York University.
RATIONALE FOR STRUCTURE OF PROCEDURES
As described above (see Introduction), PLHA-NOA experience
numerous barriers to ART. As a result, PLHA may not fill ART
prescriptions written for them, may fill them but not take ART,
may sell ART to a pharmacy, or may stop taking ART, but may not
feel comfortable disclosing their ART decisions to providers (45).
Thus, although providers generally discuss ART with patients and
monitor clinical indicators of treatment effects at regular inter-
vals – assuming patients present for care – providers may not
know for certain if an individual is taking ART. This complicates
efforts to determine whether an individual is taking ART for the
purposes of research: participants may be motivated to obscure
the fact that they are actually taking ART to enroll in the study,
and on the other hand, participants who are not taking ART may
be hesitant to disclose this fact, particularly in cases where the
provider believes they are taking ART. Thus, in light of potentially
conflicting information from providers, the medical record, and
patients, in at least a minority of cases, procedures were developed
to attempt to tease out which patients were not on ART and who
therefore met this study inclusion criterion, as we describe below
(see Figure 1).
RECRUITMENT AND ENROLLMENT
Clinic sample
Extraction of health information from themedical record. From
the medical record, the HIV clinics identified participants (1) aged
18 years or older, (2) African-American or Latino/Hispanic, (3)
HIV infected for ≥6 months, (4) medically eligible for ART for
≥3 months, (5) had seen a provider at the clinic at least once in
the past year, (6) last CD4 count <500 cells/mL, (7) able to con-
duct research activities in English, and (8) with indications that the
patient may not be taking ART including (a) medical record indi-
cates patient is not on ART (e.g.,ART refused,ART not prescribed)
or (b) patient has been prescribed ART for at least 3 months but
has detectable viral load (>1000 copies/ppmL), and (9) patient
does not have any condition that in the opinion of the primary
care provider would interfere with provision of informed con-
sent or make it unsafe for the patient to participate in this study.
Patients meeting these criteria were included on a “recruitment
roster.” Determination of ART status (i.e., never took ART or took
ART in the past but on fewer than 60 days in the past 6 months
and not at all in the past 30 days) tool place in a subsequent step,
as described in the next section.
FIGURE 1 | Enrollment procedures.
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Screening visit. Patients on the recruitment roster were either
met in person at the time of their next clinic appointment or
contacted by phone by a clinic staff member (depending on the
policies of the clinic), and invited to a screening visit, called a
“health check up” (HCU). Participants gave signed informed con-
sent before participating in the screening visit. The screening visit
had two main goals: (1) engagement and relationship building and
(2) evaluation of ART status to determine whether the patient was
eligible for the study. The screening interview alternated between
structured assessment instrument segments using the computer-
assisted personal interview format (CAPI), and open discussion
of pre-specified questions health and ART issues. Thus we also
collected other demographic and health information, which were
included in the research record if the patient enrolled in the study.
The open-ended discussion component was guided by the motiva-
tional interviewing approach (54) to encourage frank discussion
of sensitive subjects (e.g., medication selling, having stopped ART
but not yet having told the provider), to convey respect for auton-
omy, and reduce fear and social-desirability bias (54). With respect
to the ART inclusion criterion, participants were coded as (10a)
never took ART; (10b) took ART in the past but not in the past
6 months; (10c) took ART in the past but on fewer than 60 days in
the past 6 months and not at all in the past 30 days (because PLHA
may initiate ART but stop after a brief period); and (10d) took ART
on more than 60 days in the past 6 months or took ART in the past
month. Those in categories 10a–10c were eligible for the study
and those coded as category 10d were ineligible and were referred
to adherence counseling or their provider, as appropriate. Those
found eligible based on all inclusion criteria assessed from the
medical record, provider, and this screening interview were then
invited to participate in the larger research study. The screening
visit took place at the HIV clinic sites. Participants received com-
pensation of $30 plus funds for local transportation for this visit.
In keeping with the exploratory nature of the study, when the med-
ical record and participants’ reports were discrepant with respect
to ART initiation (namely, the participant stated that he/she was
not taking ART but the provider or medical record indicated
he/she most likely had initiated it), participants were enrolled into
the study. Participants gave consent for data from the medical
record data, which were recorded on a Medical Report Form, to be
included in the research record. Otherwise, they were destroyed.
Study enrollment and baseline assessment. After providing
signed informed consent for remaining study activities, par-
ticipants found eligible for the study engaged in a structured
baseline assessment on HIV knowledge, a range of attitudes
toward and beliefs about ART, and health care use patterns on
a computer, lasting approximately 1 h. The assessment was con-
ducted in both computer-assisted audio interviewing (CAPI)
and audio, computer-assisted self-interviewing (ACASI) formats.
Assessments took place at the HIV clinics. Participants received $20
and fare for local public transportation for their time. Clinic- and
peer-recruited participants completed the same set of measures,
which focused on the lifetime and past 6 months. The amount
of time to enroll participants into the clinic-recruited cohort
was 3–6 weeks, with participants typically being enrolled within
4 weeks.
Peer-recruited cohort
Peer samplingmethod. Participants were recruited using a chain-
referral peer sampling method (53). Initial recruiters (N = 88)
were drawn from a pre-existing recruitment registry of HIV-
infected individuals maintained by the research study team. Indi-
viduals in the recruitment registry who met inclusion criteria were
also eligible for the study (N = 9 enrolled). We also provided other
peer-recruited study participants with the opportunity to recruit
their own peers. Recruiters were given up to 10 coded recruitment
coupons and instructed to provide these coupons to HIV-infected
individuals who they knew by name or face, who may not be on
ART or engaged in health care (a proxy for delaying, declining,
or discontinuing ART). To protect confidentiality, peers contacted
the study directly to be screened for eligibility. Recruiters received
compensation of $10 for each peer who contacted the study and
was screened. We also accepted direct referrals from participants
who had heard about the study in the community, and recruited
directly at number of community-based organizations. The order
of study activities for the peer-recruitment cohort differed in some
respects from those described above, because we did not have a
pre-established relationship with the health care providers of these
participants, and did not have access to their medical records at the
time the participant presented to the study, as we describe below.
Brief pre-screening health interview todetermine provisional eli-
gibility. Peer-referred individuals contacted the study, and were
scheduled for a brief pre-screening health interview conducted in
person at a project field site. Participants gave verbal informed
consent for this activity. Inclusion criteria for this first stage of eli-
gibility included (1) aged 18 years or older, (2) African-American
or Latino/Hispanic, (3) HIV infected for ≥6 months, (4) able to
conduct research activities in English, (5a) never took ART or
(5b) took ART in the past but on fewer than 60 days in the past
6 months and not at all in the past 30 days. To meet the CD4 cri-
terion we assessed whether (6a) last CD4≤ 500 cells/mL or (6b)
the participant had not had CD4 tested in past year or (6c) he/she
did not know his/her CD4 count. These criteria were assessed
by self-report and were later confirmed by the medical record
where possible. HIV status was confirmed with medical docu-
mentation prior to enrollment (examples include test results from
a lab or testing site, local HIV benefits eligibility card). Partici-
pants who meet these criteria were provisionally eligible to enroll
in the study. They received compensation of $15 and fare for local
transportation for this brief interview.
Participant-assisted chart abstraction for medical report form.
As noted above (see Extraction of health information from the
medical record), two inclusion criteria are reported by the partic-
ipant’s health care provider (#4 – medically eligible for ART for
≥3 months; #9 – whether the patient had any condition that would
interfere with provision of informed consent or make it unsafe).
Peer-recruited participants provisionally eligible at screening pro-
vided signed informed consent for the project to have the health
care provider complete a Medical Report Form with these and
other inclusion criteria drawn from the medical record. Alter-
nately, participants could ask the provider themselves to complete
the form. Participants received compensation of $15 for having the
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Medical Report Form completed. In keeping with the exploratory
nature of the present study, participants not linked to health care
(defined as not engaging in any HIV-related health care visits in
past year) could remain in the study, and were referred to HIV care
during the study.
Screening visit to establish eligibility. As described above (see
Screening visit), participants engaged in a screening visit with
structured and open-ended components to determine eligibility
with respect to ART status. Participants received compensation of
$30 for this session, plus fare for local transportation.
Enrollment and assessment. Participants who met the inclusion
criteria provided signed informed consent to be enrolled in the
study, and participated in the structured baseline interview as
described above (see Study enrollment and baseline assessment).
The amount of time to enroll participants into the peer-recruited
cohort was 1–8 weeks, with participants typically being enrolled
within 6 weeks.
MEASURES
Socio-demographic, background, and health characteristics
We assessed socio-demographic characteristics such as age, sex,
race/ethnicity, sexual minority status, and employment status with
a structured measure (55). We assessed HIV history including year
of first HIV diagnosis, time between diagnosis and engagement in
health care, current health status (at a level of good or better), nadir
and most recent CD4 levels, most recent viral load levels, and ART
history with a measure from the HIV cost and services utilization
study (HCSUS) (56). HIV-related symptoms were assessed with
the symptoms distress module (57). The module uses a five-point
scale, which is summed to characterize the extent of symptom dis-
tress experienced (Cronbach’s α= 0.87). HIV care utilization in
the past 6 months was assessed with items from the service utiliza-
tion battery (58). We assessed 11 reasons for discontinuing ART
using a scale developed by Johnson and colleagues (yes/no) (18).
Individual/attitudinal influences
HIV treatment knowledge. Treatment knowledge was assessed
on a reliable 14-item three-point scale (true, false, and not sure,
Cronbach’s α= 0.76). Treatment knowledge was scored as the
number of items answered correctly (range 0–14) (59).
Mistrust. General medical mistrust, that is, mistrust of the health-
care system in general, was assessed with a seven-item assessment
using a five-point Likert-type scale (strongly disagree to strongly
agree) (Cronbach’s α= 0.72). After reverse coding of one item, the
total score was the average across the items, which ranged from 0 to
4, with a higher number indicating greater mistrust (60). HIV and
ART mistrust was assessed with a reliable (Cronbach’s α= 0.84)
10-item measure that assesses attitudes toward healthcare organi-
zations that provide HIV care and HIV medication on a five-point
Likert-type scale (strongly disagree to strongly agree) (61). After
reverse coding of two items, the total score was the average across
items, which ranged from 0 to 4, with a higher number indicat-
ing greater mistrust. Mistrust in one’s health care provider was
assessed by the trust in physician scale (62), an 11-item measure
assessing measuring dependability, confidence, and confidentiality
of information on a five-point Likert-type scale (strongly disagree
to strongly agree) (Cronbach’sα= 0.88). All items were coded such
that a higher number indicated greater mistrust. The total score
was the average across items, which ranged from 0 to 4.
ART health beliefs. Antiretroviral therapy taking self-efficacy
was assessed with a 17-item highly reliable measure that uses a
10-point Likert scale, with higher scores indicating greater HIV
medication-taking self-efficacy (Cronbach’s α= 0.95) (63). ART
outcome expectancies, in this case, are the participant’s confidence
that ART will have beneficial health and quality of life outcomes
if taken, were assessed on a nine-item measure that uses a 10-
point Likert scale with higher scores indicating more positive
ART outcome expectancies (Cronbach’s α= 0.95) (63). Further,
the beliefs about medication questionnaire (BMQ) (64) is a 13
item scale comprising two subscales measuring beliefs about med-
ications, revised to assess beliefs about ART: personal necessity for
ART (e.g., my health in the future will depend on these medica-
tions, Cronbach’s α= 0.88) and concern/fear about effects of ART
(e.g., the idea of taking HIV medications worries me, Cronbach’s
α= 0.68). Participants indicate that the degree of agreement with
individual statements about ART on a five-point Likert scale ranges
from 1= strongly disagree to 5= strongly agree. Scores obtained
for the individual items within each scale are summed to give a
scale score.
“Readiness” to take ART. “Readiness” to take ART at the present
time was assessed using two items, modeled on the approach devel-
oped by Rollnick (65): the perceived importance of taking ART and
confidence that he/she could take HIV medication every day, as
prescribed, if he/she so desired (65). Both were assessed on a 0–10
scale and these two ratings were multiplied to create the “readi-
ness”variable, leading to a range from 0 to 100, where higher scores
indicate greater readiness for ART.
Social factors
ART-related stigma. Concern about stigma associated with ART
was assessed with three items drawn from the Patient Medication
Adherence Questionnaire (66) (e.g., I don’t want people to see me
take my HIV medicines), assessed on a three-point scale (disagree,
not sure, and agree). Each item was scored from 1 to 3, and the total
score was the average across items, with a higher score indicating
greater stigma (Cronbach’s α= 0.73).
Social norms supportive of ART. Egocentric social norms sup-
portive of ART were assessed using a single item tapping into
the extent to which social network members living with HIV are
perceived as favorable toward or currently taking ART using a
seven-point Likert-type scale ranging from none to almost all
social network members (how many of the people you know who
are living with HIV or AIDS would consider taking HIV medica-
tion?) (67). External injunctive social norms, the extent to which
participants perceive close friends and family as encouraging or
supporting the participant to take ART, were assessed with a sin-
gle item using a seven-point Likert-type scale ranging from none
to almost all social network members (how many of your close
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friends and family would support you if you started HIV medica-
tion?) (67). Internal norms supportive of ART (how you feel about
things others may do?) were assessed with a single item using a
four-point Likert-type scale (strongly disagree to strongly agree)
that was reverse coded (I think people who take HIV medications
are making a mistake.) (67).
Structural factors
Received care in a hospital clinic. Using a single item we assessed
whether participants received care in a hospital HIV clinic, which
tend to be larger and provide a comprehensive set of high-quality
health, mental health, and social services, vs. other settings (private
practice, community setting, and emergency room).
Satisfaction with health care. Satisfaction with health care was
assessed with the Client Satisfaction Survey (68), a four-item mea-
sure that uses a four-point Likert scale. Individual items were
scored from 0 to 3, with higher numbers indicating greater sat-
isfaction. The total score was the average across items (Cron-
bach’s α= 0.85). Satisfaction with care could be considered an
individual/attitudinal-level variable, but was used as a proxy for
setting quality in this study.
Selling ART. Participants were asked, “People have told us that
in tough times, they have sold their HIV medication to others in
order to pay for necessities. In your whole life, have you ever had
to sell your HIV medications?” Participants were also asked if they
had sold ART over the past 6 months. Both items were scored as
yes/no.
MISSING DATA
Missing data were handled by the multiple imputation method,
which is more powerful and less biased than ad hoc methods
of handling missingness (e.g., listwise deletion). This approach
assumes that data are missing at random (MAR), that is, MAR
conditional on values observed. Missing data were imputed 100
times using a chained equation approach (69), as implemented by
the R Core Team (70) MICE package (71). Estimates and standard
errors from complete-data analyses of these 100 imputed datasets
were combined into a single inference (point estimate, standard
error, and confidence interval) using the approach described by
Rubin (72). Details on the extent of missing data are provided in
the tables. The variables with the largest percentage of missing data
included medical records-based viral load (52%) and CD4 (36%),
which we were unable to obtain from health care providers or
medical institutions for some in the peer-recruited cohort. Across
all other study variables, less than half of all variables had any
missing data, and data were missing for at most 8% of participants
(the “egocentric norms supportive of ART” measure).
DATA ANALYSIS
Bivariate linear regression was used to estimate associations
between potential predictors and ART readiness. Then, multi-
ple regression analysis was used to examine, among the variables
with a significant bivariate association with ART readiness, which
variables also had a significant unique association with ART readi-
ness. The R statistical computing environment was used for all
analyses (70).
RESULTS
FEASIBILITY OF ENROLLING IN CLINICS AND THROUGH
PEER-REFERRAL
Clinic cohort
The total number of patients at the two HIV clinics was 4758,
of which 206 (4.3% of the clinic population) were not on ART
and 148 met preliminary eligibility criteria. These 148 individuals
(3.1% of the clinic population) were targeted for screening and, if
eligible, enrolled. Of these, we were unable to contact 99 (66.9%),
often because participants did not present for appointments at
the scheduled times and we were therefore unable to recruit them.
Further, eight individuals declined to participate (5.4%), providers
did not approve participation in six cases (4.1%); and eight were
found to be ineligible in the screening meeting (5.4%). A total
of 35 (23.7% of the 148 found preliminarily eligible) were found
eligible and were enrolled.
Peer-recruited cohort
A total of 135 were pre-screened through peer-referral (N = 108),
the recruitment registry (N = 15), and directly recruitment
from community-based organizations (N = 12). Most (N = 119;
88.2%) were found preliminarily eligible based on self-report data.
Next, of these 119 potential participants, we obtained medical
report forms to confirm inclusion criteria from 55 participants
(46.2%). We found that 26 were ineligible (N = 22, CD4> 500;
N = 3 provider reported patients was taking ART and patient con-
firmed in the screening meeting; N = 1 provider did not consent
to patient participating). The remaining 29 were found eligible
(N = 11 provider reported the patient was on ART but the patient
reported not taking it; N = 8 provider was unsure if the patient
was taking ART; N = 10 provider reported patient was not on
ART). For 34, the medical report form was waived because the
participant reported not having seen a health care provider in the
past year. A total of 60 peer-recruited participants were enrolled,
50.4% of the 119 found preliminarily eligible.
SOCIO-DEMOGRAPHIC AND HEALTH CHARACTERISTICS
Socio-demographic and other characteristics of the sample are
described in Table 1. Approximately 60% of the sample was
male and the mean age was 48.2 years (SD= 8.88 years). More
than two-thirds (76.8%) of participants were African-American,
and the remainder was Latino/Hispanic (23.2%). More than a
third (39.0%) was a “sexual minority” (lesbian, gay, or bisex-
ual). Few were currently employed (16.8%), but most had a high
school diploma or equivalent (66.3%). Those in the peer-recruited
cohort were significantly older and less likely to be employed,
but did not differ from their clinic-recruited peers on other
socio-demographic characteristics. Participants had been diag-
nosed with HIV for 14.7 years on average (SD= 8.73 years). At first
diagnosis, 40% had delayed entering care for more than 6 months.
The most recent CD4 count from the medical report forms was
302.8 cells/mL on average (SD= 138.9 cells/mL) and log10 viral
load was 3.49 (SD= 1.36). Self-reported CD4 were comparable to
the medical record data: 343.06 cells/mL (SD= 128.57 cells/mL),
as was viral load. About half (56.8%) had taken ART in the past.
Almost all (99.0%) reported that their provider had recommended
that they take ART over their lifetimes. About three-quarters
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Table 1 | Socio-demographic, background, and health characteristics.
Clinic (N =35)
Mean (SD)/%
Peer-referred (N =60)
Mean (SD)/%
Total (N =95)
Mean (SD)/%
p
Age in years 44.8 (10.8) 49.9 (7.0) 48.0 (8.9) *
Male sex 65.7 58.3 61.1
African-American, not Latino/Hispanic 71.4 80.0 76.8
Latino/Hispanic 28.6 20.0 23.2
Sexual minority status (gay, lesbian, and bisexual) 48.6 33.3 39.0
Currently employed 28.6 10.0 16.8 *
HEALTH
Years since HIV diagnosis (self-report) 12.1 (9.1) 16.13 (8.2) 14.65 (8.7) *
>6 months between HIV diagnosis and care appointment 25.7 48.3 40.0 *
Health self-rating “good” or better 77.1 61.7 67.4
CD4 nadir/lowest CD4 cell count ever 246.0 (142.4) 136.6 (116.6) 173.6 (135.3) **
Most recent CD4 (medical report form) 344.8 (128.6) 249.9 (135.4) 302.8 (138.9) **
Most recent CD4 (self-report) 343.1 (127.1) 254.3 (143.4) 291.7 (143.0) **
Most recent log10 viral load (medical report form) 3.9 (0.9) 2.9 (1.7) 3.5 (1.4) *
Most recent log10 viral load (self-report) 3.9 (1.1) 3.2 (1.5) 3.4 (1.4) *
Health care provider recommended ART (lifetime) 100.0 98.3 99.0
Medical provider knows not taking HIV medications at this time 100.0 88.3 92.6 *
>1 HIV health care appointments in the past 6 months 88.6 61.7 71.6 **
Symptoms distress module (0–72) 16.9 (15.8) 18.7 (13.7) 18.0 (14.5)
Ever taken ART 42.9 65.0 56.8 §
Categorical variables compared via Fisher’s exact test and other variables via independent samples t-test, without assuming equal variances. Data were missing for
the following variables: CD4 nadir (24); recent CD4 report form (34); recent CD4 self-report (12); viral load report form (49); and viral load self-report (40). **p≥0.01
level, *p≥0.05 level, §p≥0.10 level.
(71.6%) had attended one or more HIV care appointments in the
past 6 months. Rates of HIV-related symptoms were modest on
average (18.03 on average on a 0–72 scale; SD= 14.46). Compared
to their clinic-recruited peers, the peer-recruited cohort exhibited
worse health outcomes on almost every index, as shown in Table 1.
REASONS FOR ART DISCONTINUATION
As presented in Table 2, among those who had taken ART pre-
viously, the main reasons for participants’ discontinuing ART in
the past were side effects (68.6%), “changed my mind” (62.0%),
“life circumstances changed” (54.9%), difficulties with adherence
(47.1%), substance use got in the way (45.1%), and “was not
ready” (39.2%). About half (52.9%) reported other reasons for
discontinuing ART in an open item question, which included the
following: ART was taken only during pregnancy and the partic-
ipant did not wish to continue, difficulty swallowing or dislike of
pills, fear of long-term toxicity, stigma, felt healthy, did not wish
to accept one had HIV, and medication selling. Peer-recruited par-
ticipants differed from their peers in a number of respects: they
were significantly more likely to report the following reasons for
discontinuation than the clinic-recruited cohort: losing housing,
life circumstances changed, substance use, changed their minds,
and not being ready.
MULTI-LEVEL BARRIERS TO ART
Individual/attitudinal-level factors
Participants answered an average of 68.5% of items correctly,
with no differences between cohorts (9.55 items correct on the
Table 2 | Reasons for ART discontinuation.
Clinic
(N =14)
(%)
Peer-
referred
(N =37) (%)
Total
(N =51)
(%)
P
Difficulties with adherence 28.6 54.1 47.1
Side effects 50.0 75.7 68.6
Lost housing 0.0 24.3 17.7 *
Provider told me to stop 21.4 13.5 15.7
Friends or family told me to stop 7.1 5.4 5.9
Problems getting prescription filled 0.0 10.8 7.8
Life circumstances changed 7.1 73.0 54.9 **
Substance use got in the way 14.3 56.8 45.1 *
Changed my mind 28.6 75.0 62.0 **
Was not ready 14.3 48.7 39.2 *
Other reason 78.6 43.2 53.0 *
Comparisons made by Fisher’s Exact test. Data were missing for the following
variables: items 1–8, 10, and 11 (3); item 9 (4). **p≥0.01 level, *p≥0.05 level.
knowledge scale, SD= 3.02 items) as shown in Table 3. Levels
of general, HIV, and health care provider mistrust were moder-
ate with no difference between cohorts. Mean scores were 2.08
(SD= 0.66), 2.36 (0.65), and 2.48 (0.7), respectively, correspond-
ing to “neutral” on the five-point scale. Self-efficacy scores indi-
cated that participants’ views on their abilities to manage ART
were neutral (mean 6.52 on 1–10 scale, SD= 2.13), with no cohort
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Table 3 | Knowledge of, attitudes toward, and access to ART.
Clinic (N =35)
Mean (SD)/%
Peer-referred (N =60)
Mean (SD)/%
Total (N =95)
Mean (SD)/%
p
INDIVIDUAL-ATTITUDINAL FACTORS
HIV treatment knowledge (0–14) 9.3 (2.9) 9.7 (3.1) 9.6 (3.0)
HIV medication distrust (0–4) 2.1 (0.7) 2.1 (0.6) 2.1 (0.7)
General medical distrust (0–4) 2.3 (0.7) 2.4 (0.6) 2.4 (0.7)
Physician distrust (0–4) 1.4 (0.7) 1.6 (0.7) 1.5 (0.7)
ART self-efficacy beliefs (0–10) 6.8 (1.8) 6.3 (2.3) 6.5 (2.1)
ART outcome expectancies (0–10) 6.9 (2.7) 7.3 (2.5) 7.1 (2.5)
Personal necessity for ART (0–4) 1.8 (0.9) 2.2 (0.8) 2.1 (0.9) *
Concern about/fear of ART (0–4) 2.5 (0.7) 2.3 (0.6) 2.4 (0.6) *
“Readiness” for ART (0–100) 41.8 (36.5) 33.0 (33.0) 36.2 (34.4)
SOCIAL FACTORS
Stigma (1–3) 1.9 (0.9) 2.0 (0.6) 2.0 (0.7)
Egocentric norms supportive of ART (0–6) 4.8 (1.5) 3.5 (1.8) 3.9 (1.8) **
External injunctive norms supportive of ART (0–6) 4.6 (2.2) 4.7 (1.9) 4.7 (2.0)
Internal norms supportive of ART (0–6) 4.1 (1.5) 4.3 (1.1) 4.2 (1.2)
STRUCTURAL FACTORS
Receive HIV care in a hospital clinic 100.0 31.7 56.8 **
Satisfaction with health care (0–3) 2.2 (0.6) 1.8 (0.8) 1.9 (0.7) **
Ever sold ART 14.3 26.7 22.1
Sold ART in the past 6 months 5.7 1.7 3.2
Categorical variables compared via Fisher’s exact test and other variables via independent samples t-test, without assuming equal variances. Data were missing for
the following variables: ART readiness (3); egocentric norms (8); external norms (4); internal norms (6); and client satisfaction (7). **p≥0.01 level, *p≥0.05 level.
differences. Similarly, outcome expectancies, that is, whether
ART is beneficial, were in the positive range for both cohorts
(mean= 7.12 on a 1–10 scale, SD= 2.53). Personal necessity for
ART was moderate (mean= 2.08 on a 0–4 scale which corre-
sponds to an answer of “neutral,” SD= 0.88). Concern about/fear
of ART was also moderate (mean= 2.36 on a 0–4 scale which
corresponds to an answer of “neutral,” SD= 0.63). “Readiness”
to take ART was modest for both cohorts, with a mean score of
36.23 (SD= 34.38). The two cohorts were similar to each other
on these individual/attitudinal factors as shown in Table 3 with
two exceptions: the peer-referred cohort reported significantly
higher personal necessity for ART, but lower concern about/fear
of ART.
Social-level influences
Both cohorts reported similar concerns about stigma as a bar-
rier to ART (X = 1.99 on a 1–3 scale; SD= 0.72). Perceived social
norms (egocentric, external, and internal) were also in the neu-
tral range (3.9–4.7 on 0–6 scale). Peer-recruited participants had
significantly more negative egocentric norms (suggesting that they
view fewer of their peers as favorable toward ART), but did not dif-
fer on external or internal norms compared to the clinic-recruited
cohort.
Structural-level influences
About half received HIV care in a hospital-based clinic: all of those
in the clinic-recruited cohort (as expected) and 31.7% of the peer-
recruited cohort. Satisfaction with care tended to be satisfactory
(X = 1.94 on a 0–3 scale, SD= 0.7) but the peer-recruited cohort
reported lower satisfaction compared to the clinic cohort. A total of
22.1% had ever sold medication in the past across the two cohorts.
DIFFERENCES BETWEEN THOSE WHO HAVE DISCONTINUED ART AND
THOSE WHO HAVE NEVER TAKEN ART (ART NAÏVE)
Compared to those who have never taken ART (that is,ART naïve),
PLHA who had discontinued ART tended to be significantly older
[mean= 49.9 (SD= 8.0) years vs. 45.5 (SD= 9.4) years, p≤ 0.05];
had lived with HIV longer [mean= 16.9 (SD= 7.6) years vs. 11.6
(SD= 9.3) years, p≤ 0.01]; had higher levels of HIV knowledge
[mean= 10.4 (SD= 2.5) vs. 8.4 (SD= 3.3)]; had lower levels of
concern about ART [mean= 2.1 (SD= 0.6) vs. 2.7 (SD= 0.5),
p< 0.001]; and lower levels of perceived stigma [mean= 1.9
(SD= 0.7) vs. 2.2 (SD= 0.7), p< 0.05]. The cohorts were simi-
lar to each other on remaining health, putative barriers to ART,
and whether care was received in a hospital clinic or not. (Data
not shown on a table for parsimony.)
FACTORS ASSOCIATED WITH READINESS TO INITIATE ART
As noted above (see Individual/attitudinal-level factors), readiness
for ART was low, although there was great variability. In bivari-
ate analyses, readiness for ART was not associated with cohort
(clinic vs. peer) or any socio-demographic or health/health history
variable. Instead, a number of individual/attitudinal and social-
level factors were predictive. Physician mistrust (B=−10.4) was
negatively associated with readiness for ART at a statistically sig-
nificant level, while self-efficacy beliefs (B= 5.5), positive outcome
expectancies (B= 6.3), favorable beliefs about the personal neces-
sity of ART (B= 17.5), and positive internal norms (B= 7.9) were
Frontiers in Public Health | HIV and AIDS July 2014 | Volume 2 | Article 81 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gwadz et al. ART delay, decline, and discontinuation
Table 4 | Correlations among variables associated with ART readiness.
1 2 3 4 5 6
ART readiness
(0–100)
1.00
Physician mistrust
(0–4)
−0.22* 1.00
ART self-efficacy
beliefs (0–10)
0.34** −0.24* 1.00
ART outcome
expectancies (0–10)
0.48** −0.33** 0.36** 1.00
Personal necessity
for ART (0–4)
0.46** −0.20 0.15 0.69** 1.00
Internal norms in
support of ART (0–6)
0.30** −0.26* 0.28** 0.51** 0.50** 1.00
*p<0.05; **p<0.01.
positively associated with readiness for ART. In Table 4, we present
a correlation matrix of the variables found to be associated with
readiness for ART. Correlations with ART readiness show medium
to large effect sizes (73) and relationships are in the expected
direction. In a multiple regression of ART readiness on the five
variables with a significant bivariate association, only ART self-
efficacy (B= 3.6) and personal necessity beliefs (B= 11.54) had
significant unique associations with ART readiness.
DISCUSSION
The present study provides a detailed exploration of a vulnera-
ble and hard-to-reach population, PLHA-NOA, and extends past
research on PLHA-NOA to include those not embedded in hos-
pital clinic settings. Indeed, diverse recruitment and engagement
approaches are necessary for this population, given that at least
half of PLHA are estimated to not engage in HIV care at the
recommended frequency (3). We focused on African-American
and Latino/Hispanic individuals in the present study because they
comprise the majority of PLHA and experience a unique set of
barriers to ART, partly rooted in culture. Indeed, understanding
these barriers can inform efficient, effective, and culturally targeted
interventions (15).
FEASIBILITY OF REACHING PLHA-NOA AND LESSONS LEARNED
Contrary to expectations, we found that it was challenging to
recruit PLHA-NOA in clinic settings in the context of this study,
but more feasible to do so using a peer-recruitment method. Sev-
eral factors impeded recruitment in the hospital HIV clinics. First,
most PLHA in these settings (>95%) were taking ART, highlight-
ing the success of these high-quality care settings in engaging
patients and bringing them on ART in a timely fashion. Yet among
those in clinics not on ART, patterns of infrequent attendance
at medical care appointments greatly reduced their chances of
participation, in part because providers were unable to confirm
the patient’s appropriateness for the study and because they did
not present for recruitment. Further, when they did present for
recruitment, these PLHA were often disinterested in discussing
ART use, in many cases, expressing fear of and anxiety related
to doing so. This suggests that novel strategies to engage wary
patients are needed. Peer-driven interventions may be one promis-
ing approach. In peer-driven intervention, the initial contact is
made by a peer rather than a study or clinic staff member (74, 75).
This can foster engagement because peers tend to have a high level
of credibility (74,75). Study findings also suggest that self-selection
and/or structural barriers reduce the numbers of PLHA with the
most serious barriers to ART in clinic settings; these individu-
als may feel more comfortable in non-medical community-based
settings, and non-HIV settings such as harm reduction organiza-
tions. The present study also provides important information on
whether PLHA-NOA are socially networked with each other. The
rapid rate of peer-recruitment suggests that large numbers of them
are socially networked, which provides the basis for future studies
of this population using social network recruitment approaches.
Our study findings further suggest that clinic settings can draw
on outreach approaches to engage PLHA-NOA in HIV care at
appropriate levels and address barriers to ART.
The present study was consistent with existing literature on
hospital clinic vs. community-based settings in some respects (49,
50): PLHA-NOA recruited from the clinics tended to have better
health status indicators, even when not taking ART. Yet perhaps
in contrast to this past literature, those in non-clinic settings were
presented to the study in later stages of HIV disease (although we
do not know when they first engaged with the health care setting).
Overall, the present study indicates that PLHA recruited through
peers, most of whom are not embedded in HIV hospital clinics, are
farther along in the course of their HIV disease and have greater
contextual risk factors than those in clinics.
We found that an in-depth screening process fostered engage-
ment with the study and, overall, more accurate reporting of
ART status. This study component can be retained in the future
research. Yet we also found it challenging to confirm medical
information from the providers of a substantial number of the
peer-recruited cohort, mainly because they were poorly engaged
in care.Yet confirmation of HIV health status (CD4, viral load) and
ART status (taking vs. not taking) is vital to studies such as these.
Indeed, PLHA-NOA commonly report that communication with
providers is challenging (76). It is possible that a small number
of participants in the present study were taking ART but did not
report it to the study in order to enroll. Future studies can consider
evaluating CD4 and viral load directly (that is, not relying on the
medical record), and recent ART use can be assessed through hair
samples (77), to more definitely assess HIV indicators and recent
ART use patterns.
REASONS FOR ART DISCONTINUATION
Among those who had taken ART in the past, participants tended
to discontinue their regimens for reasons that appear largely
preventable or addressable. Participants did not report difficul-
ties obtaining ART or ART prescription refills, highlighting the
strength of the local HIV care system in proving patients with
access to ART. Instead, contextual changes (e.g., life circumstances
changed, lost housing), substance use, and factors suggesting a low
level of readiness for ART (e.g., changed my mind, was not ready)
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contributed to ART discontinuation, particularly among those in
the peer-recruited cohorts. This suggests that interventions and
programs in clinical settings to increase readiness for ART may also
promote sustained ART use (78). Side effects were the single most
common reason for discontinuation, consistent with past research
(79, 80). Yet participants can be prepared for side effects through
interventions to improve coping skills for self-management (81) or
training on mindfulness based stress reduction (82). Participants
who initiated ART some time ago may not realize that the toler-
ability of regimens has improved, and patient education on the
side effect profiles of newer regimens may boost ART uptake (83).
Yet PLHA from racial/ethnic minority backgrounds, particularly
older PLHA, vividly recall the early days of the HIV epidemic
when AZT (Zidovudine) was given in high doses, resulting in
side effects including anemia, neutropenia, hepatotoxicity, and
myopathy (84). Thus for PLHA from racial/ethnic minority back-
grounds, an understanding of ART side effects may be interpreted
through a filter of suspicion and medical distrust that is more com-
mon among people from racial/ethnic minority backgrounds than
Whites, as we have described above (see Introduction) (20). This
suggests that interventions to increase ART uptake acknowledge
this cultural history and, importantly, address the emotions associ-
ated with ART use, particularly fear, in addition to providing health
education and fostering adherence skills. Indeed, the role of fear
of ART in the problem of PLHA-NOA cannot be over-emphasized
(51, 85). In future research, we will use quantitative and qualitative
research to better understand the issue of side effects, including
how PLHA learn about side effects, which side effects cause the
greatest concerns, and what types of intervention approaches can
help PLHA manage their fear of side effects and the side effects
themselves.
MULTI-LEVEL BARRIERS TO ART
An understanding of barriers to ART can inform the design of
programs to improve ART uptake with high adherence. The liter-
ature suggests that PLHA-NOA have low levels of HIV knowledge
and largely negative attitudes toward ART. Although our ability to
interpret study data is somewhat limited by the lack of published
norms, findings suggest that knowledge of HIV treatment was at
least adequate (average 69% items correct), albeit with room for
improvement, and attitudes toward ART ranged from somewhat
negative to neutral. As might be expected in a sample of PLHA-
NOA, readiness to initiate ART was low [mean 36.2 (SD= 34.4)
on a 0–100 point scale], but with substantial variability. Overall,
participants in the two cohorts evidenced similar rates of barri-
ers to ART, although those in the peer-recruited cohort reported
greater perceived need for ART, perhaps consistent with their infe-
rior health status and lower rates of concern about/fear of ART,
compared to those recruited from clinics.
FACTORS ASSOCIATED WITH READINESS TO INITIATE ART
Readiness to initiate ART has been found in a number studies to
predict treatment outcomes and adherence, and may be an impor-
tant target for interventions to improve ART uptake. We did not
find that socio-demographic or health factors were associated with
readiness in this sample. A number of attitudes and beliefs were
associated with greater readiness, including higher levels of trust in
one’s physician, self-efficacy, outcome expectancies, perceived per-
sonal need for ART, and positive perceived internal norms (how
one feels about others taking ART). This suggests that attitudes
toward ART are complex and multifaceted, and include individual
and social aspects, and that these various aspects of ART beliefs
must be considered together to improve readiness for ART and
ART uptake. Horne and colleagues (86) found that uptake of
ART was associated with perceptions of personal necessity and
concerns about potential adverse effects, and these factors pre-
dicted subsequent adherence, independent of clinical variables and
depression (86). The present study suggests a number of other
social-cognitive factors that may influence these behaviors. Coun-
seling approaches such as motivational interviewing are useful to
“unpack” complex and ambivalent attitudes, and thereby enhance
intrinsic motivation for health behavior change (54).
THOSE WHO HAVE NEVER TAKEN ART PREVIOUSLY (TREATMENT
NAÏVE)
We found that PLHA who had never taken ART in the past, called
“treatment naïve PLHA,” differ from those with past ART experi-
ence. These treatment naïve PLHA tended to present with a pattern
of more serious barriers to ART than their ART-experienced peers,
including being less knowledgeable about ART, and evidencing
greater fears of ART and of ART-related stigma. Future interven-
tion efforts can take into consideration that younger PLHA and
those who have lived with HIV for shorter periods of time may
require more support in order to initiate and benefit from ART,
in comparison to their peers who have had more time to adapt
to their HIV diagnoses and gain knowledge about ART. Yet we do
not know at present whether treatment naïve PLHA are less likely
than their experienced peers to initiate ART, a question which can
be explored in the future research.
ART INITIATION CANNOT BE DISENTANGLED FROM ADHERENCE
The problem of delayed ART initiation cannot be considered sep-
arately from that of ART adherence. Despite recent advances in
ART regimens’ tolerability and efficacy, and potent new technolo-
gies to monitor adherence, the problem of fostering long-term
adherence to ART remains one of the greatest challenges facing
the public health field today (87, 88). A large body of litera-
ture has examined the effects of social/behavioral interventions
to improve ART adherence with respect to medication-taking
behavior and clinical outcomes (87–92). A number of promising
adherence interventions had emerged in the last decade, evidenc-
ing effects on adherence behavior and viral load (93–96). Yet a
review by Simoni and colleagues found that while overall adher-
ence interventions increased the chances of high ART adherence
compared to controls, the effect on clinical outcomes (viral load in
this case) was not statistically significant, and these effects tend to
be short-lived (91). Further, many adherence interventions found
successful in experimental trials may not be feasible for implemen-
tation in community-based settings and real-world clinics (88). In
a recent meta-analysis, de Bruin and colleagues found that non-
white patients had a lower chance of achieving undetectable viral
load compared to whites. However, they did not find racial/ethnic
differences in adherence success rates. They speculated these viral
load differences may have been caused by pre-treatment clinical
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status, or that adherence differences were not found due to a lack of
adherence measures with cross-cultural validity (90). Thus efforts
to develop behavioral interventions to improve ART initiation can
benefit from and build on this rich literature in the domain of ART
adherence, with particular attention to non-white PLHA, who may
experience the greatest barriers to adherence and/or good clinical
outcomes.
LIMITATIONS
The present study’s limitations include a lack of knowledge of
the true size and scope of this vulnerable population, as well as
the relatively small sample sizes which may have prevented us
from detecting differences between cohorts. Further, the conve-
nience sampling approach may limit the generalizability of study
findings to other settings. In addition, the low proportion of
clinic-recruited PLHA suggests that those enrolled may not be rep-
resentative of the larger population of PLHA in clinics; they may
represent those most willing to consider ART, thus biasing find-
ings toward more favorable outcomes. Moreover, the ability of the
present study to examine complex relationships across multiple
variables was limited by sample size. Structural equation mod-
eling in larger samples is therefore needed to better understand
processes that promote or impede readiness for ART. Last, the
present study was exploratory in nature and targeted PLHA able
to conduct research activities in English. We will extend future
research to mono-lingual Spanish-speaking PLHA, although the
size of this population appears small in our local area (<5% of
PLHA) (97).
IMPLICATIONS FOR FUTURE RESEARCH AND PRACTICE
To achieve the goals of the National HIV/AIDS Strategy (NHAS),
PLHA must initiate ART in a timely fashion, and remain on ART
with high adherence through their lives. Studies on the HIV con-
tinuum of care indicate that improvements are needed at each
stage, and the CDC calls for particular efforts to reduce health
disparities by race and ethnicity (3). The present study advances
our knowledge of a vulnerable and hard-to-find population of
PLHA that is critical to efforts to reduce gaps along the HIV con-
tinuum of care. Importantly, the results of this study and recent
conceptualizations of the HIV continuum of care in low-resource,
international settings (98) strongly suggest that engagement in
care and use of ART are not static,but entail ongoing,multi-faceted
processes. Future work is needed to articulate a more detailed HIV
continuum of care with a focus on intermediate steps between
linkage to care, engagement in care, ART initiation, and ART con-
tinuation with high adherence, and devise intervention strategies
for improving outcomes along this more detailed care continuum.
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